

Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.
You can purchase shares of Moleculin Biotech (NASDAQ:MBRX) through any online brokerage.
Other companies in Moleculin Biotech’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Moleculin Biotech has a consensus price target of $2015.00.
The stock price for Moleculin Biotech (NASDAQ: MBRX) is $8.68 last updated November 10, 2026 at 2:27 PM EST.
There are no upcoming dividends for Moleculin Biotech.
Moleculin Biotech does not have any upcoming earnings scheduled.
There is no upcoming split for Moleculin Biotech.
Moleculin Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat...